Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in development for Parkinson's Disease.
週一，hepion pharmaceuticals通過與晚期臨床階段的以色列私人公司Pharma Two b Ltd.達成了明確的合併協議，該公司正在開發一種針對帕金森病的組合產品候選藥物P2B001。
The merger is valued at an estimated pro-forma implied equity value of approximately $58.5 million.
本併購估值約爲5850萬美元的擬議股權價值。
Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B.
Hepion將合併併成爲Pharma Two b的間接全資子公司。
The combined company will continue to operate under the "Pharma Two B" name. Pharma Two B has agreed to file a registration statement with the SEC to register the ordinary shares proposed to be issued to Hepion's equity holders in the acquisition. It will also apply to list its ordinary shares on Nasdaq under the ticker symbol "PHTB."
合併後的公司將繼續使用“Pharma Two B”名稱。Pharma Two b已同意向SEC提交註冊聲明，以註冊擬出售給Hepion股權持有人的普通股。其還將申請將其普通股在納斯達克以“PHTb”股票代碼上市。
"P2B001 offers a novel, easy-to-use therapeutic approach, that is designed to address the unmet need for an effective, safe, once-daily, no titration required treatment with a lower incidence of excessive daytime sleepiness—a common side effect of currently available dopamine agonist treatments in Parkinson's disease patients" said Dan Teleman, Chief Executive Officer of Pharma Two B.
Pharma Two b的首席執行官Dan Teleman表示：“P2B001提供了一種新穎、易於使用的治療方法，旨在滿足帕金森病患者治療需求的未滿足之處。該療法無需逐漸增加劑量，一天只需服用一次，並且副作用低——目前可用的多巴胺激動劑治療常見副作用爲過度晝間嗜睡。”
"Our company is in a stage that we believe meets the public market and investors' expectations. We are excited about Pharma Two B's next growth phase, moving P2B001 towards an NDA submission targeted for the first half of 2026 and making this potential treatment available to patients," he continued.
他繼續說：“我們的公司已達到公衆市場和投資者的期望。我們對Pharma Two B的下一個增長階段，將P2B001推向2026年上半年的NDA提出階段並向患者提供這種治療的前景感到興奮。”
Hepion has also announced a private placement of $2.9 million non-convertible senior notes to qualified institutional investors.
Hepion還宣佈向符合資格的機構投資者進行了290萬美元的不可轉換優先債券的定向增發。
Pharma Two B has entered into a securities purchase agreement for an $11.5 million private placement of ordinary shares and accompanying Series A warrants and Series B warrants.
Pharma Two b已與證券購買協議簽署，進行了1150萬美元的普通股和附帶的A類認股權證和B類認股權證的定向增發。
In April, Hepion Pharmaceuticals began wind-down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as previously announced in December 2023.
2023年12月前已宣佈的公告中，Hepion Pharmaceuticals在ASCEND-NASH試驗中開始了縮減活動，同時繼續探索戰略性選擇。
Price Action: HEPA stock is up 1.96% at $1.04 during the premarket session at last check Monday.
股票代碼爲HEPA的股票週一盤前交易中漲幅爲1.96%，報價爲1.04美元。